Regeneron Pharmaceuticals Inc. Buys New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 4,444,445 shares of the biopharmaceutical company’s stock, valued at approximately $1,045,822,000. Alnylam Pharmaceuticals comprises 95.5% of Regeneron Pharmaceuticals Inc.’s investment portfolio, making the stock its biggest holding. Regeneron Pharmaceuticals Inc. owned 3.45% of Alnylam Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Huntington National Bank grew its stake in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Larson Financial Group LLC grew its stake in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $33,000. True Wealth Design LLC boosted its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the last quarter. Finally, OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $35,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $233.07 on Tuesday. The business has a 50 day simple moving average of $254.70 and a two-hundred day simple moving average of $261.25. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a market capitalization of $30.17 billion, a P/E ratio of -107.41 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on ALNY shares. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Sanford C. Bernstein lowered their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, Chardan Capital restated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $304.26.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,752 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the sale, the chief marketing officer now owns 15,705 shares of the company’s stock, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,986 shares of company stock valued at $20,397,849. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.